Salarius Pharmaceuticals Regains Compliance with All Nasdaq Listing Requirements

Core Points - Salarius Pharmaceuticals has regained compliance with Nasdaq Listing Rule 5550(b)(1), the Equity Standard Requirement, as of October 10, 2025, following its earlier compliance with Listing Rule 5550(a)(2) on September 9, 2025 [1][2] Group 1: Compliance and Merger - The company is now fully compliant with all Nasdaq listing requirements, which is a significant step towards its planned merger with Decoy Therapeutics [2] - Salarius entered into a definitive merger agreement with Decoy Therapeutics on January 13, 2025, where Decoy will merge with a wholly owned subsidiary of Salarius, forming a new entity named Decoy Therapeutics [3] - Following the compliance notice, Salarius will be under a Mandatory Panel Monitor for one year, during which any non-compliance could lead to a delisting determination [4] Group 2: Merger Details and Pipeline - The merger is expected to create multiple value-creating opportunities through Decoy's pipeline of peptide conjugate therapeutics, which targets unmet medical needs in respiratory infectious diseases and GI oncology [5] - The combined company will focus on advancing Decoy's lead asset, a pan-coronavirus antiviral, and other programs targeting flu, COVID-19, RSV, and GI cancers [7] - Salarius' existing drug candidate, SP-3164, will be integrated into the new company's drug development strategy [5][6] Group 3: Company Backgrounds - Decoy Therapeutics is a preclinical-stage biotechnology company utilizing machine learning and AI for rapid design and manufacturing of peptide conjugate drug candidates [9] - Salarius Pharmaceuticals is a clinical-stage biopharmaceutical company with two drug candidates focused on cancer treatment, including seclidemstat and SP-3164 [10][11]